中文
Licensing

Articles 1

Puhe BioPharma and Bayer Enter into Global License Agreement for Clinical Phase I PRMT5 Inhibitor
Puhe BioPharma and Bayer Enter into Global License Agreement for Clinical Phase I PRMT5 Inhibitor
Licensing

Suzhou Puhe BioPharma Co.,Ltd. and Bayer today announced that they have entered into a global license agreement for Puhe BioPharma’s oral, small molecule PRMT5 inhibitor that selectively targets MTAP-deleted tumors

2025-03-26
About Us
Company Profile Development History Company Layout
Business Development
R&D System Product Pipelines Patient Recruitment
Strategic Cooperation
External License Out-licensing In-licensing
News Center
Company News
Join Us
Corporate Culture Hot Jobs
Contact Us
Contact Information Feedback
官方公众号

Scan to follow
the official public account

Links
拾玉
GO

Copyright 2025 Suzhou Puhe Biopharma Co., Ltd. 苏 ICP备 2023036064

Site Map Privacy Policy Legal Notices